Compare Gilead Sciences, Inc. (GILD) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs PubMatic Inc — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while PubMatic Inc trades at $18.64 (market cap $850.88M). The key difference: Gilead Sciences, Inc. is far larger — about 214.4× PubMatic Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while PubMatic Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and PubMatic Inc for 40 Days on average.
| GILD | PUBM | |
|---|---|---|
Market Cap | $182.40B | $850.88M |
Volume | 4,469,821 | 997,698 |
Sector | Health | Technology |
52-Week High | $155.80 | $19.18 |
52-Week Low | $117.18 | $6.28 |
Typical Hold Time | 111 Days | 40 Days |
Enterprise Value | $205.46B | $754.01M |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, showing modest daily gains of 0.17% with strong technical support at $145. The company demonstrates robust fundamentals with Q2 2026 earnings beating expectations despite a net loss, while maintaining a high gross margin of 79.59%. Recent developments include expanded HIV prevention drug access across Latin America through a PAHO partnership, positioning the company for growth in key therapeutic areas.
GILD presents a mixed outlook with strong analyst support (65.5% buy ratings) and a $151.57 price target offering 3% upside, but faces headwinds from negative net income margins and elevated debt levels. The stock's valuation appears reasonable with a P/E of 17.84, though investors should monitor the company's ability to translate top-line strength into sustainable profitability amid competitive pressures.
PUBM trades at $18.68, up 0.59% today, with a bullish technical signal supported by moving averages. The company reported a net loss of $14.46 million in 2025 despite revenue of $282.93 million, though recent quarters have shown earnings beats. Analyst sentiment is positive with a $19.89 consensus price target and 11 buy ratings. Recent news highlights AI-driven ad tech growth and leadership changes, including a new global chief revenue officer.
The outlook is cautiously optimistic given strong analyst support and technical momentum, but profitability challenges and competitive pressures in digital advertising pose risks. Revenue growth and margin improvement in higher-margin segments like mobile and CTV are key catalysts for upside, while execution risks and market volatility remain concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
